These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22217384)

  • 1. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?
    Alphs L; Benedetti F; Fleischhacker WW; Kane JM
    Int J Neuropsychopharmacol; 2012 Aug; 15(7):1003-14. PubMed ID: 22217384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
    Kemp AS; Schooler NR; Kalali AH; Alphs L; Anand R; Awad G; Davidson M; Dubé S; Ereshefsky L; Gharabawi G; Leon AC; Lepine JP; Potkin SG; Vermeulen A
    Schizophr Bull; 2010 May; 36(3):504-9. PubMed ID: 18723840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal detection and placebo response in schizophrenia: parallels with depression.
    Mallinckrodt CH; Zhang L; Prucka WR; Millen BA
    Psychopharmacol Bull; 2010; 43(1):53-72. PubMed ID: 20581800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenge to atypical antipsychotic drug effect on cognition.
    Carpenter WT; Conley RR
    Am J Psychiatry; 2007 Dec; 164(12):1910-1; author reply 1911-2. PubMed ID: 18056250
    [No Abstract]   [Full Text] [Related]  

  • 5. Modelling and simulation of placebo effect: application to drug development in schizophrenia.
    Pilla Reddy V; Kozielska M; de Greef R; Vermeulen A; Proost JH
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):377-88. PubMed ID: 23315146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo reconsidered.
    Volavka J
    Can J Psychiatry; 1995 Sep; 40(7):426-7. PubMed ID: 8548725
    [No Abstract]   [Full Text] [Related]  

  • 10. Increasing placebo response in antipsychotic trials: a clinical perspective.
    Dold M; Kasper S
    Evid Based Ment Health; 2015 Aug; 18(3):77-9. PubMed ID: 26124311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The placebo effect: general information and specificities in psychiatry (depression and schizophrenia)].
    Corfmat J; Januel D; Braha S; Moulier V
    Encephale; 2012 Feb; 38(1):50-7. PubMed ID: 22381724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo response in refractory tardive akathisia.
    Remington G; Fornazzari L; Sethna R
    Can J Psychiatry; 1993 May; 38(4):248-50. PubMed ID: 8100184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.
    Kozielska M; Pilla Reddy V; Johnson M; de Ridder F; Vermeulen A; Liu J; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):53-8. PubMed ID: 23434198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.
    Gispen-de Wied C; Stoyanova V; Yu Y; Isaac M; Pani L; de Andres-Trelles F
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):804-11. PubMed ID: 22704716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response.
    Leucht S; Chaimani A; Leucht C; Huhn M; Mavridis D; Helfer B; Samara M; Cipriani A; Geddes JR; Salanti G; Davis JM
    Schizophr Res; 2018 Nov; 201():315-323. PubMed ID: 29804928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Leucht S; Leucht C; Huhn M; Chaimani A; Mavridis D; Helfer B; Samara M; Rabaioli M; Bächer S; Cipriani A; Geddes JR; Salanti G; Davis JM
    Am J Psychiatry; 2017 Oct; 174(10):927-942. PubMed ID: 28541090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia: recent advances in psychopharmacology.
    Sharma T
    Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500
    [No Abstract]   [Full Text] [Related]  

  • 19. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.